Cyril Allouche is CAO at Revance Therapeutics, Inc. (RVNC). They have made 1 open-market trade across 1 company since 2018, most recently 2019-03-18.
CIK 0001744573
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RVNC | 6,400 | $23K |
Shares reported on the most recent Form 4, priced at the 2019-03-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | SELL · 10b5-1 | 2019-03-18 | 2019-03-19 | $15.48 | $8K | -3.4% | -17.3% | -30.6% |
| RVNC | SELL · 10b5-1 | 2019-01-22 | 2019-01-23 | $17.77 | $11K | -1.5% | +2.2% | -20.8% |
| RVNC | SELL · 10b5-1 | 2019-01-03 | 2019-01-04 | $19.48 | $7K | -12.0% | -17.9% | -26.9% |
| RVNC | SELL · 10b5-1 | 2018-11-20 | 2018-11-21 | $20.66 | $10K | +21.9% | -11.6% | -13.5% |
| RVNC | SELL | 2018-11-09 | 2018-11-09 | $23.72 | $104K | -11.8% | -1.4% | -27.5% |
| RVNC | SELL · 10b5-1 | 2018-07-06 | 2018-07-06 | $28.35 | $11K | -1.9% | -8.7% | -18.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.